(Q33494038)

27 July 2017

Phase I study of WR-2721 and carboplatin (English)

1 reference

27 July 2017

1 reference

Budd GT

1

1 reference

27 July 2017

Ganapathi R

2

1 reference

27 July 2017

Bauer L

3

1 reference

27 July 2017

Murthy S

4

1 reference

27 July 2017

Adelstein D

5

1 reference

27 July 2017

Weick J

6

1 reference

27 July 2017

Gibson V

7

1 reference

27 July 2017

McLain D

8

1 reference

27 July 2017

Sergi J

9

1 reference

27 July 2017

Bukowski RM

10

1 reference

27 July 2017

1 January 1993

1 reference

European Journal of Cancer

27 July 2017

1 reference

27 July 2017

29A

1 reference

27 July 2017

8

1 reference

27 July 2017

1122-1127

1 reference

In vitro studies on the absorption of WR-2721 by tumors and normal tissues

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Phase I/II trials of WR-2721 and cis-platinum

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Protection by WR-2721 of human bone marrow function following irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Results of NCI-sponsored phase I trials with carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Pharmacokinetics of WR-2721.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Analysis of Total Platinum in Tissue Samples by Flameless Atomic Absorption Spectrophotometry. Elimination of the Need for Sample Digestion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

JANA: a new iterative polyexponential curve stripping program.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980301-6

7 January 2021

10.1016/S0959-8049(05)80301-6

Identifiers

DOI

1 reference

27 July 2017

1 reference